Chardan Capital Thinks Tocagen Inc’s Stock is Going to Recover


Tocagen Inc (NASDAQ: TOCA) received a Buy rating and a $30 price target from Chardan Capital analyst Gbola Amusa today. The company’s shares closed yesterday at $8.39, close to its 52-week low of $7.52.

According to TipRanks.com, Amusa is a 5-star analyst with an average return of 26.1% and a 55.4% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Applied Genetic Technologies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tocagen Inc with a $19.88 average price target, representing a 136.9% upside. In a report issued on August 24, H.C. Wainwright also maintained a Buy rating on the stock with a $14.50 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $14.66 and a one-year low of $7.52. Currently, Tocagen Inc has an average volume of 112.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy compan. It focuses on the development of product candidates designed to activate a patient’s immune system against their own cancer from within. It is in the business of discovery, development, and commercialization of products for the treatment of cancer.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts